What Is ARA-290 / Cibinetide?
Cibinetide is an experimental 11-amino-acid peptide derived from the three-dimensional surface of erythropoietin. It was originally called ARA-290 and has also been described as pyroglutamate helix B surface peptide.
It was designed to preserve proposed tissue-protective and anti-inflammatory signals while avoiding erythropoietin’s stimulation of red-blood-cell production. Researchers have studied it in small-fibre neuropathy associated with sarcoidosis and diabetes, as well as diabetic macular oedema and other inflammatory conditions.
Small controlled studies reported encouraging changes in symptoms and corneal nerve fibres. The evidence remains early. Cibinetide is not an approved medicine and has not been established as a general recovery, injury-healing or anti-ageing peptide.
How is it related to erythropoietin?
Erythropoietin, or EPO, is a glycoprotein hormone best known for stimulating the bone marrow to make red blood cells. Laboratory work proposed that tissue-protective effects used a receptor complex different from the classical blood-forming receptor.
Cibinetide copies a small spatial region from EPO’s helix B rather than the whole hormone sequence. Its N-terminal pyroglutamate and cyclised design help define the molecule. It is not EPO and should not be expected to reproduce EPO’s pharmacology.
The proposed innate-repair receptor is described as a complex involving the EPO receptor and beta-common receptor CD131. The receptor model and downstream interpretation remain areas of scientific debate, so it is safer to describe measured effects than to present the pathway as settled fact.
What does “non-erythropoietic” mean?
Classical EPO signalling promotes survival and maturation of red-cell precursors. Therapeutic EPO can therefore raise haemoglobin and haematocrit, which is useful in selected anaemias but can create risks when stimulation is excessive or inappropriate.
Cibinetide was designed to avoid that blood-forming receptor activity. Short human studies monitored haematology and did not show an EPO-like increase in red-cell mass. That supports the intended separation, but it does not mean the peptide is biologically inactive outside the target tissue or free from every vascular, immune or metabolic effect.
“Non-erythropoietic” is consequently a pharmacological description, not a general safety certification. The clinical question remains whether any tissue-protective signal is large, durable and selective enough to improve outcomes.
How was cibinetide developed?
Researchers separated EPO’s blood-forming action from tissue-protection hypotheses, then designed smaller peptides intended to retain the latter. ARA-290 advanced through animal models of nerve, metabolic and inflammatory injury.
The design is often called a helix-B surface peptide because it mimics residues presented on one exposed face of EPO rather than reproducing the hormone’s complete sequence. Pyroglutamate at the N-terminus and cyclisation help create a constrained structure intended to display that surface and improve resistance to breakdown.
That molecular logic is plausible but does not settle the receptor question. Evidence for an EPOR-CD131 repair complex has been debated, including how the components assemble and whether observed effects are mediated through the proposed receptor in every tissue. Clinical interpretation should therefore rest on randomized outcomes rather than receptor diagrams alone.
| Period | Development |
|---|---|
| 2000s | Non-erythropoietic EPO-derived tissue-protection concepts developed |
| Early 2010s | Pilot clinical work began in sarcoidosis-associated small-fibre neuropathy |
| 2013 to 2017 | Controlled neuropathy studies reported symptom and corneal-nerve findings |
| Later studies | Diabetes, diabetic macular oedema and other inflammatory settings explored |
| Current position | Investigational and not approved |
What is small-fibre neuropathy?
Small nerve fibres carry pain and temperature signals and help regulate sweating, heart rate and blood-vessel tone. Damage can cause burning pain, altered sensation, dizziness, palpitations and gastrointestinal or sweating symptoms.
Routine nerve-conduction studies assess larger fibres and may be normal. Skin biopsy can count small nerve fibres. Corneal confocal microscopy uses a specialised microscope to image small nerves in the cornea without removing tissue.
An increase in corneal nerve-fibre density may indicate biological regeneration, but it is a surrogate. Patients ultimately care about pain, function, autonomic symptoms and durable quality of life.
Why use the cornea to study a body-wide neuropathy?
The cornea has a dense network of small sensory nerves that can be imaged repeatedly with confocal microscopy. This gives researchers a non-invasive way to quantify nerve-fibre length, density, branching or area without taking serial skin biopsies.
Corneal measures can change with diabetes and other neuropathies, but they are not identical to nerve structure in the feet, skin or autonomic organs. Image acquisition, selected fields and analysis methods can affect estimates. A numerical increase is most persuasive when it occurs alongside consistent improvements in symptoms and function.
The method is therefore valuable as a biological marker and possible trial endpoint. It is not direct proof that painful fibres throughout the body regenerated or that long-term disability was prevented.
What did the sarcoidosis trials find?
One double-blind pilot enrolled 22 people with sarcoidosis and symptoms of small-fibre neuropathy. Participants received intravenous ARA-290 or placebo three times weekly for four weeks. The trial was exploratory and primarily assessed safety and symptom signals.
A later blinded, placebo-controlled study used daily subcutaneous treatment for 28 days. It reported improvement in neuropathic symptom measures, corneal small-nerve-fibre density, temperature sensitivity and six-minute walking.
A later Phase IIb study enrolled 64 participants and focused more directly on corneal nerve-fibre area and regenerating fibres in skin. Twenty-eight days is remarkably short for a chronic neuropathy, so the structural findings attracted attention. However, short duration also leaves uncertainty about persistence after treatment and whether a surrogate change produces lasting clinical benefit.
Follow-up analysis linked increased corneal nerve abundance with other measures. The convergence of structural and symptom signals is encouraging, but the samples were small, treatment was short and multiple outcomes were assessed. Replication in larger trials with durable patient-centred endpoints is needed.
The studies also involved a specific disease context: sarcoidosis-associated small-fibre loss. Sarcoidosis is an inflammatory disorder, and its neuropathy may not respond like chemotherapy neuropathy, idiopathic neuropathy or nerve damage caused by longstanding diabetes. Evidence should not be transferred between these conditions without testing.
What did the diabetes study find?
A Phase II study enrolled people with type 2 diabetes and painful neuropathy. It reported improvements in selected neuropathic symptoms and metabolic measures, with corneal-nerve findings in a subgroup that had reduced fibres at baseline.
The reported symptom difference favoured cibinetide over 28 days, while the corneal result was clearest among participants whose baseline nerve-fibre density was already abnormally low. This is biologically understandable—there is less room to demonstrate “regrowth” when a measure begins near normal—but it also makes the finding dependent on subgroup definition.
Subgroup findings are less secure than a pre-specified primary result in the whole randomised group. Regression to the mean, multiple comparisons and baseline differences can create apparent signals. The result justifies further testing rather than clinical adoption.
What happened in diabetic macular oedema research?
An open-label Phase II study examined cibinetide in diabetic macular oedema. Open-label means both participants and investigators know treatment is being given, making subjective outcomes and changes over time harder to attribute.
The study was extremely small: nine participants were recruited and eight completed 12 weeks. It did not show improvement in best-corrected visual acuity, central retinal thickness, retinal sensitivity or tear production. A patient-reported visual-function score changed, but without a control group that result is difficult to interpret.
Eye imaging can provide objective measurements, but a single-centre uncontrolled study cannot separate treatment from natural fluctuation, concurrent care or selection. It should not be used as evidence that systemic cibinetide treats all diabetic eye disease.
How is cibinetide synthesised?
An 11-amino-acid peptide can be assembled using solid-phase peptide synthesis. The process joins protected amino-acid building blocks in sequence on a resin. Cibinetide’s pyroglutamate and cyclisation require controlled chemistry and confirmation.
Purification can use high-performance liquid chromatography. Mass spectrometry and sequence-sensitive methods test identity. Related peptide impurities, incomplete cyclisation, oxidation, counterions, residual solvents, content and biological potency also matter.
For injectable use, validated sterility, endotoxin, particle and stability testing are separate requirements. A research-vial purity percentage does not establish clinical equivalence.
What would a credible identity package need to establish?
Testing should distinguish the intended cyclic 11-residue molecule from linear, truncated, incorrectly cyclised or oxidised material. Intact mass, peptide mapping or sequence-sensitive analysis, chromatographic related-substance methods and a functional potency assay provide different pieces of evidence.
Peptide content also matters because the weighed powder can include water and counterions. For an injectable preparation, concentration accuracy, sterility, bacterial endotoxin, particles, container integrity and stability require validated controls.
Even a well-characterized chemical copy would not create evidence for sports recovery or general anti-inflammatory use. Analytical identity answers “what is in the vial”; it does not answer “does this improve a clinical outcome?”
What is known about safety?
Early trials were designed partly to show that cibinetide did not raise haemoglobin or haematocrit like EPO. Short studies reported generally acceptable tolerability, but their size and duration cannot rule out uncommon immune, cardiovascular or organ effects.
The peptide’s proposed anti-inflammatory and tissue-protective actions could behave differently in infection, malignancy or chronic immune disease. Long-term exposure has not been characterised through a large approval programme.
Is cibinetide approved?
No. Cibinetide is not an FDA-, EMA- or UK-approved medicine. It should not be described as an approved treatment for neuropathy or sarcoidosis.
Clinical-guideline discussion of an investigational therapy is not marketing authorisation. Neither is a registered trial.
How strong is the evidence overall?
| Question | Best available evidence | Defensible conclusion |
|---|---|---|
| Does cibinetide avoid an EPO-like rise in red-cell mass? | Short early human studies | The intended non-erythropoietic profile is supported over limited exposure |
| Does it affect neuropathy biomarkers? | Small randomized studies using corneal and skin nerve measures | Biological activity is plausible and surrogate improvements were reported |
| Does it provide durable pain or functional benefit? | Short trials with modest samples and multiple outcomes | Not established |
| Does it treat diabetic macular oedema? | Tiny uncontrolled study without improvement in key objective eye measures | No efficacy conclusion |
| Is it a general repair or recovery peptide? | No adequate controlled evidence | No |
The research base is large enough to explain why cibinetide remains interesting, but too small and short to establish routine treatment. Larger confirmatory trials with durable patient-centred outcomes are the missing step.
What claims are not established?
Cibinetide has not been established for sports recovery, tendon or muscle healing, general inflammation, healthy ageing, brain enhancement or prevention of diabetic complications. It has not supplied a validated self-use dose or cycle.
Frequently asked questions
Is ARA-290 the same as cibinetide?
Yes. ARA-290 is the earlier development name.
How many amino acids does it contain?
Eleven.
Is it erythropoietin?
No. It was designed from one EPO surface region and lacks the full hormone.
Does it increase red blood cells?
It was designed to avoid erythropoietic activity, and early studies did not show an EPO-like rise.
Has it been tested in people?
Yes, in small early trials including sarcoidosis-associated and diabetic neuropathy.
Did it regrow nerves?
Studies reported increased corneal nerve-fibre measures, a surrogate that needs larger confirmation.
Does it treat pain?
Some small trials reported symptom improvement, but definitive efficacy is not established.
Is cibinetide approved?
No.
Is it a general repair peptide?
No. That label goes beyond the condition-specific evidence.
Are online products equivalent to trial material?
No. Identity, cyclisation, amount, sterility and stability require verification.
Are study administration levels recommendations?
No. They are research context only.
Sources
Research reviewed through September 2026.